NZ599930A - Pharmaceutical compositions for the stimulation of stem cells. - Google Patents
Pharmaceutical compositions for the stimulation of stem cells.Info
- Publication number
- NZ599930A NZ599930A NZ599930A NZ59993010A NZ599930A NZ 599930 A NZ599930 A NZ 599930A NZ 599930 A NZ599930 A NZ 599930A NZ 59993010 A NZ59993010 A NZ 59993010A NZ 599930 A NZ599930 A NZ 599930A
- Authority
- NZ
- New Zealand
- Prior art keywords
- stem cells
- stimulation
- pharmaceutical compositions
- composition
- disclosed
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000000130 stem cell Anatomy 0.000 title abstract 2
- 230000000638 stimulation Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- LKBSMPFEKIBRGC-UHFFFAOYSA-N 2-[[2-(4-methoxyanilino)-4-pyrimidinyl]amino]ethanol Chemical compound C1=CC(OC)=CC=C1NC1=NC=CC(NCCO)=N1 LKBSMPFEKIBRGC-UHFFFAOYSA-N 0.000 abstract 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 abstract 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 abstract 1
- 102100028892 Cardiotrophin-1 Human genes 0.000 abstract 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 108010023082 activin A Proteins 0.000 abstract 1
- 239000002269 analeptic agent Substances 0.000 abstract 1
- 108010041776 cardiotrophin 1 Proteins 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2009066251 | 2009-12-02 | ||
| PCT/EP2010/068700 WO2011067317A1 (fr) | 2009-12-02 | 2010-12-02 | Compositions pharmaceutiques pour la stimulation des cellules souches |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599930A true NZ599930A (en) | 2014-04-30 |
Family
ID=42316097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599930A NZ599930A (en) | 2009-12-02 | 2010-12-02 | Pharmaceutical compositions for the stimulation of stem cells. |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JP2013512877A (fr) |
| KR (1) | KR20120099751A (fr) |
| CN (1) | CN102711798A (fr) |
| AU (1) | AU2010326633A1 (fr) |
| BR (1) | BR112012013164A2 (fr) |
| CA (1) | CA2781493A1 (fr) |
| IL (1) | IL219901A0 (fr) |
| MX (1) | MX2012005976A (fr) |
| NZ (1) | NZ599930A (fr) |
| RU (1) | RU2012120834A (fr) |
| TW (1) | TW201141510A (fr) |
| WO (1) | WO2011067317A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6538081B2 (ja) * | 2014-07-07 | 2019-07-03 | メディポスト カンパニー リミテッド | 刺激を受けた幹細胞の馴化培地の発毛促進能およびそれらの使用 |
| CN105079791A (zh) * | 2015-09-18 | 2015-11-25 | 郑榆坤 | 一种刺激体内内源干细胞的组合物及其应用 |
| RU2634576C1 (ru) * | 2016-10-24 | 2017-10-31 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ стимуляции регенерации тканей |
| CN107050428B (zh) * | 2017-03-23 | 2020-05-05 | 温州医科大学 | Fgf20药物及其对脑创伤的治疗应用 |
| CN107648592B (zh) * | 2017-11-13 | 2021-05-14 | 深圳市喆邦生物工程有限公司 | 趋化因子ccl4作为制备治疗骨折药物的应用 |
| RU2686718C1 (ru) * | 2018-03-12 | 2019-04-30 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro |
| KR102106710B1 (ko) | 2018-10-11 | 2020-05-04 | 강원대학교산학협력단 | 인간 전분화능 줄기세포로부터 조혈모세포 및 대식세포 분화 증진 방법 |
| CN111195350A (zh) * | 2020-01-15 | 2020-05-26 | 重庆大学 | IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用 |
| WO2021187895A1 (fr) * | 2020-03-17 | 2021-09-23 | 주식회사 히에라바이오 | Composition pour la prévention ou le traitement de maladies ischémiques comprenant des cellules souches cardiaques |
| CN111621525B (zh) * | 2020-06-18 | 2021-04-23 | 中赛干细胞基因工程有限公司 | Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途 |
| CN116836920B (zh) * | 2023-08-21 | 2024-05-24 | 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 | 一种无血清培养基及其制备间充质干细胞的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2626234T3 (es) * | 2004-07-30 | 2017-07-24 | Mayo Foundation For Medical Education And Research | Tratamiento de tejido cardiovascular |
| US8168588B2 (en) * | 2005-01-25 | 2012-05-01 | Five Prime Therapeutics, Inc. | Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions |
| US9765298B2 (en) * | 2006-07-24 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Methods and materials for providing cardiac cells |
| US8481075B2 (en) * | 2007-12-13 | 2013-07-09 | Beijing Shengyiyao Science & Technology Development Co. Ltd. | Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines |
-
2010
- 2010-12-02 BR BR112012013164A patent/BR112012013164A2/pt not_active IP Right Cessation
- 2010-12-02 MX MX2012005976A patent/MX2012005976A/es unknown
- 2010-12-02 JP JP2012541498A patent/JP2013512877A/ja not_active Withdrawn
- 2010-12-02 WO PCT/EP2010/068700 patent/WO2011067317A1/fr active Application Filing
- 2010-12-02 CN CN201080053800XA patent/CN102711798A/zh active Pending
- 2010-12-02 RU RU2012120834/15A patent/RU2012120834A/ru not_active Application Discontinuation
- 2010-12-02 TW TW099141986A patent/TW201141510A/zh unknown
- 2010-12-02 AU AU2010326633A patent/AU2010326633A1/en not_active Abandoned
- 2010-12-02 NZ NZ599930A patent/NZ599930A/en not_active IP Right Cessation
- 2010-12-02 CA CA2781493A patent/CA2781493A1/fr not_active Abandoned
- 2010-12-02 KR KR1020127017238A patent/KR20120099751A/ko not_active Application Discontinuation
-
2012
- 2012-05-20 IL IL219901A patent/IL219901A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012120834A (ru) | 2014-01-20 |
| WO2011067317A1 (fr) | 2011-06-09 |
| MX2012005976A (es) | 2012-06-25 |
| BR112012013164A2 (pt) | 2016-03-01 |
| AU2010326633A1 (en) | 2012-05-31 |
| IL219901A0 (en) | 2012-07-31 |
| CN102711798A (zh) | 2012-10-03 |
| JP2013512877A (ja) | 2013-04-18 |
| KR20120099751A (ko) | 2012-09-11 |
| TW201141510A (en) | 2011-12-01 |
| CA2781493A1 (fr) | 2011-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ599930A (en) | Pharmaceutical compositions for the stimulation of stem cells. | |
| MY161593A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| MX2011008616A (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas. | |
| MX2011010859A (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. | |
| MD4430B1 (ro) | Compoziţii şi metode de tratament al hepatitei virale C | |
| ZA200503656B (en) | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline | |
| TW201129368A (en) | Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions | |
| TW200806318A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| WO2008149382A8 (fr) | Nouveaux dérivés de pyrrole-2-carboxamide en tant qu'activateurs de la glucokinase, leur procédé d'obtention et leur application pharmaceutique | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
| GB0620385D0 (en) | Novel compounds | |
| NZ700824A (en) | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients | |
| WO2006115770A3 (fr) | Preparations pharmaceutiques d'olazanpine en comprimes a desintegration orale | |
| MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
| MX2012004409A (es) | Proteina recombinante de humano cc10 para el tratamiento de la influenza. | |
| EP1778209B8 (fr) | Methodes et compositions d'administration orale de fts | |
| WO2007081486A3 (fr) | Administration orale de defensines pour traiter des maladies intestinales | |
| WO2009003694A3 (fr) | Procédé de traitement de maladies liées à un dysfonctionnement mitochondrial | |
| WO2011022633A3 (fr) | Procédé de traitement du cancer | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| NZ599499A (en) | Use of a neuregulin to treat peripheral nerve injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |